Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement.

doi:10.1002/cncr.28522

Article

Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement.

Cancer - 1 Apr 2014

Soverini Simona, De Benedittis Caterina, Papayannidis Cristina, Paolini Stefania, Venturi Claudia, Iacobucci Ilaria, Luppi Mario, Bresciani Paola, Salvucci Marzia, Russo Domenico, Sica Simona, Orlandi Ester, Intermesoli Tamara, Gozzini Antonella, Bonifacio Massimiliano, Rigolin Gian Matteo, Pane Fabrizio, Baccarani Michele, Cavo Michele, Martinelli Giovanni

Abstract excerpt

BACKGROUND: Patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) frequently relapse on imatinib with acquisition of BCR-ABL kinase domain (KD) mutations. To analyze the changes that second-generation tyrosine kinase inhibitors (TKIs) have brought in mutation frequency and type, a database review was undertaken of the results of all the BCR-ABL KD mutation analyses performed in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides

Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement.

Abstract excerpt

Topics

Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement.

Abstract excerpt

Topics

Related research